Author

Robert J. Canter

h-index 4 View on Semantic Scholar

We have 3 of 25 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer

Abstract Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) therapy, but only 25% of patients have durable responses. TG4010, a mucin 1 (MUC1) vaccine, has demonstrated activity in NSCLC. We conducted a multi-institutional study to determine the safety and activity of nivolumab plus...

Charles X. Wang, G. Luxardi, H. Mori et al. · Oncoimmunology · 0 citations

Open access Aug 2026

Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model.

The clinical successes of chimeric antigen receptor (CAR) T cells represent a major shift in immunotherapy. However, there is also increasing emphasis on potential long-term effects of CAR T cell therapy, especially using preclinical xenogeneic models. It has been previously demonstrated that only naïve, and not memory...

Wahed A. Firoz, Michael K. Sheng, Pedro Ruivo et al. · Blood Advances · 0 citations

Review Open access Aug 2026

Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach

By embedding measurement into the therapeutic design loop and prioritizing long-term safety and developmental outcomes alongside efficacy, next-generation engineered cell therapies may evolve toward adaptable, precision-guided systems capable of improving both survival and quality of life for children.

Ana M. Sandoval-Castellanos, Yumin Ahn, Robert J. Canter et al. · Progress in Biomedical Engin... · 0 citations